TG Therapeutics

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

TG Therapeutics secures FDA approval for BRIUMVI, poised for growth

TG Therapeutics' Q4 2022 performance reflects a solid financial position with a focus on efficient capital management and commercial execution.
Strengths lie in FDA approval for BRIUMVI, positive launch progress, and commitment to supporting the MS community, positioning the company for growth.
Challenges include sustaining momentum, achieving broad payer coverage, managing expenses, and navigating complexities related to clinical trials.
Opportunities exist in further data analysis, market expansion, community engagement, and strategic investments, driving future growth and differentiation.

TG Therapeutics excels with BRIUMVI launch, eyes European expansion

TG Therapeutics demonstrated strong financial stability and strategic expense management in Q1 2023, despite reporting a net loss, showcasing resilience and efficient operations.
BRIUMVI's early success in the US market, positive feedback from healthcare providers, and progress in payer coverage position the product as a competitive and promising offering in the MS treatment class.
While facing decisions on international expansion and expense optimization, TG Therapeutics remains committed to serving the MS community and improving patient outcomes with BRIUMVI.
The company's focus on market access, product efficacy, and financial prudence sets a solid foundation for future growth and success in the competitive pharmaceutical landscape.

TG Therapeutics reports stellar Q2 performance and eyes global expansion

TG Therapeutics showcased robust financial performance and market acceptance of Briumvi in Q2 2023.
While facing challenges like revenue lag and potential market competition, the company remains well-positioned.
Opportunities lie in expanding market reach, product offerings, and maximizing the potential of Briumvi.
Overall, TG Therapeutics' strategic partnerships and positive market feedback position it for continued success.

TG Therapeutics excels in Q3 with BRIUMVI's market success

TG Therapeutics had a strong Q3 performance, driven by BRIUMVI's success and revenue exceeding expectations. The company is well-positioned with a healthy cash reserve and plans for market expansion. Challenges include potential competition from BTK drugs and seasonal market fluctuations.

TG Therapeutics excels in Q4 with BRIUMVI, eyes strong growth

TG Therapeutics demonstrated robust financial performance and strategic growth plans during the Q4 2023 earnings call, driven by the successful launch of BRIUMVI.
While facing challenges such as optimizing the infusion process and managing expenses, the company's focus on innovation and market expansion positions it for future success.
With a strong emphasis on commercialization, patent protection, and revenue targets, TG Therapeutics shows promising potential for sustained growth and value creation.

TG Therapeutics reports robust Q1 results, eyes growth opportunities

TG Therapeutics' Q1 performance reflects strong revenue growth driven by Briumvi's success and strategic investments in awareness and commercialization.
While facing challenges in market share growth and profitability, the company's focus on innovation and partnerships positions it well for future opportunities.
Maintaining a healthy financial position and a commitment to R&D underscore TG Therapeutics' resilience and potential for continued growth in the autoimmune therapy space.

TG Therapeutics excels in Q2, raises guidance and focuses on growth

TG Therapeutics delivered a strong Q2 performance with notable achievements in sales, R&D, and financial stability. While facing challenges related to internal controls and VA contract impact, the company is well-positioned to capitalize on opportunities for growth through market expansion and strategic initiatives.

TG Therapeutics reports robust Q3 earnings and outlines growth strategies

TG Therapeutics (TGTX) delivered a strong performance in Q3 2024, driven by the success of BRIUMVI and strategic growth initiatives.
While facing challenges in market competition and product development, TGTX remains focused on innovation, expansion, and maximizing shareholder value.
The company's financial strength, successful partnerships, and clear growth strategies position TGTX for continued success and future growth in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

Esperion Therapeutics

Karyopharm Therapeutics

Risk-taking investors flock to biotech for its constant flow of events that can spike or crush the stock prices of the companies developing the latest therapies.

Biotech's Most Volatile Binary Events for Q1

TG Therapeutics (TGTX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

TG Therapeutics (TGTX) Catches Eye: Stock Jumps 8.9%

Company anticipates ending 2019 with approximately $140 million in cash, providing funding well into 2021 Company anticipates ending 2019 with approximately $140 million in cash, providing funding well into 2021

TG Therapeutics Announces $50.0 Million Registered Direct Public Offering of Common Stock to a Single Institutional Investor

With two pivotal data readouts and potentially three NDA filings coming in the next twelve months, it is time to revisit TG Therapeutics.

Revisiting TG Therapeutics

TG Therapeutics (TGTX) announces positive first clinical data from its once daily, oral, BTK inhibitor, TG-1701, as a single agent and as a triple therapy in combination.

TG Therapeutics' Shares Soar on Positive Early-Stage Data

Precision Biosciences

Forty Seven Inc

Mustang Bio

Roche Holding AG

The American Society of Hematology's 61st annual meeting is underway in Orlando, Florida.

5 Stocks Moving On ASH Presentations

A triple-combination therapy from the company triggered responses in 100% of patients with difficult-to-treat blood cancers.

Here's Why TG Therapeutics Rose as Much as 36.7% Today

Shares of TG Therapeutics Inc. TGTX, -7.29% gained 16% in premarket trading on positive data from small early-stage studies testing TG-1701 as a standalone therapy in patients with relapsed/refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

TG Therapeutics shares rise on early-stage clinical data

TG Therapeutics, Inc. (TGTX) CEO Michael Weiss on Q3 2019 Results - Earnings Call Transcript

TG Therapeutics Could Be About To Deliver On Rich Promise

Combination was well tolerated with no new safety signals identified with median follow-up of >4 years

TG Therapeutics Announces Final Long-Term Results from the Phase 3 GENUINE Study Demonstrated that Ublituximab in Combination with Ibrutinib Improved Progression-Free Survival in Patients with High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia as 

The company has given back most of its 2019 gains, but does this change its previously bullish appraisal?

Is TG Therapeutics a Buy?

Presentation scheduled for today, Wednesday, October 2, 2019 at 4:10 PM ET Presentation scheduled for today, Wednesday, October 2, 2019 at 4:10 PM ET

TG Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

U2 combination was generally well-tolerated with relatively low rates of immune-mediated toxicities

TG Therapeutics Announces Publication of Clinical Data from the Phase I/Ib Combination Trial of Ublituximab and Umbralisib (“U2”) in Blood

Phase 2 study of umbralisib monotherapy in BTK/PI3K-delta intolerant CLL reports an estimated median progression-free survival (PFS) of 23.5 months (n=50) with 58% of patients on umbralisib longer than their prior kinase inhibitor therapy

TG Therapeutics Announces Data Presentations at the XVIII International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

Presentation scheduled for Tuesday, September 24, 2019 at 11:00 AM ET Presentation scheduled for Tuesday, September 24, 2019 at 11:00 AM ET

TG Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

NEW YORK, Sept.  12, 2019  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today presented the first look at the ULTIMATE I & II Phase 3 trial design and demographic data and updated Phase 2 extension trial data for ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of multiple sclerosis (RMS) at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held in Stockholm, Sweden.

TG Therapeutics Presents Data for Ublituximab at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

Presentations include Phase 3 ULTIMATE program study design and patient demographic information, and long-term safety data from the Phase 2 trial of ublituximab in MS Presentations include Phase 3 ULTIMATE program study design and patient demographic information, and long-term safety data from the Phase 2 trial of ublituximab in MS

TG Therapeutics Announces Data Presentations at the Upcoming 35th Annual Congress of ECTRIMS 

NEW YORK, Aug.  26, 2019  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) announced with great sadness the passing of longtime Board Member, Mark Schoenebaum, MD.

TG Therapeutics Mourns the Loss of Board Member, Mark Schoenebaum, MD

TG Therapeutics Inc (NASDAQ: TGTX) shares were trading higher for much of Monday's session before closing down 0.83%, and one large options trader was taking profits.

Large Option Trader Sells TG Therapeutics Calls After Big Run

TG Therapeutics, Inc. (TGTX) CEO Michael Weiss on Q2 2019 Results - Earnings Call Transcript

AbbVie

Calithera Biosciences

Carnival

Denbury Resources

GigaMedia

Macerich

Insiders may sell their stock for many reasons but they only buy it if believe they will profit. Here are 7 stocks to buy along with insiders.

7 Stocks on Sale the Insiders Are Buying

Biohaven Pharmaceutical Hld

Liberty Latin America Ltd.

Liberty Latin America

Odonate Therapeutics

According to GuruFocus Insider Data, these are the largest CEO buys during the past week.

Weekly CEO Buys Highlight (June 30)

During the past six months, TG Therapeutics is demonstrating the behavior of a bioscience stock operating at a growth inflection.

TG Therapeutics: Hitting A Growth Inflection

TG Therapeutics, Inc. (TGTX) CEO Michael Weiss on Q1 2019 Results - Earnings Call Transcript

News for TG Therapeutics Stock (TGTX)